New anticoagulants: Beyond heparin, low-molecular-weight heparin and warfarin

British Journal of Pharmacology

Volumn 144, Issue 8, 2005, Pages 1017-1028

  Bates, Shannon M ^a   Weitz, Jeffrey I ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

Anticoagulant; Antithrombotic; Arterial thromboembolism; Direct thrombin inhibitor; Pentasaccharide; Venous thromboembolism

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ALTEPLASE; ANTICOAGULANT AGENT; ANTISTASIN; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR IXA INHIBITOR; CLOPIDOGREL; COUMARIN DERIVATIVE; DABIGATRAN; DABIGATRAN ETEXILATE; DALTEPARIN; DERMATAN SULFATE; DROTRECOGIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; LY 517717; MELAGATRAN; NEMATODE ANTICOAGULANT PEPTIDE C2; PROTAMINE SULFATE; RAZAXABAN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RIVAROXABAN; THROMBIN INHIBITOR; TICK ANTICOAGULANT PEPTIDE; TPP 889; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LIVER TOXICITY; LUNG EMBOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; THROMBOGENESIS; THROMBOSIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; DRUGS, INVESTIGATIONAL; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; VENOUS THROMBOSIS; WARFARIN;

EID: 17844385569     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706153     Document Type: Review

References (135)

1. ABRAHAM, E., REINHART, K., OPAL, S., DEMEYER, I., DOIG, C., RODRIGUEZ, A.L., BEALE, R., SVOBODA, P., LATERRE, P.P., SIMON, S., LIGHT, B., SPAPEN, H., STONE, J., SEIBERT, A., PECKELSEN, C., DE DEYNE, C., POSTIER, R., PETTILA, V., ARTIGAS, A., PERCELL, S.R., SHU, V., ZWINGELSTEIN, C., TOBIAS, J., POOLE, L., STOLZENBACH, J.C., CREASEY, A.A. & OPTIMIST TRIAL STUDY GROUP (2003). Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA, 290, 238-247.
2. ABRAHAM, E., REINHART, K., SVOBODA, P., SEIBERT, A., OLTHOFF, D., DAL NOGARE, A., POSTIER, R., HEMPELMANN, G., BUTLER, T., MARTIN, E., ZWINGELSTEIN, C., PERCELL, S., SHU, V., LEIGHTON, A. & CREASEY, A.A. (2001). Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit. Care Med., 29, 8081-8089.
3. AGNELLI, G., BERGQVIST, D., COHEN, A., GALLUS, A. & GENT, M. (2003). A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus Study. J. Thromb. Haemost. (Suppl 1) (Abstr. #OC006).
4. ALBERS, G.W., DALEN, J., LAUPACIS, A., MANNING, W.J., PETERSEN, P. & SINGER, D.E. (2001). Antithrombotic therapy in atrial fibrillation. Chest, 119, 194S-206S.
5. ALEXANDER, J.H., DYKE, C.K., YANG, H., BECKER, R.C., HASSELBLAD, V., ZILLMAN, L.A., KLEIMAN, N.S., HOCHMAN, J.S., BERGER, P.B., COHEN, E.A., LINCOFF, A.M., SAINT-JACQUES, H., CHETCUTI, S., BURTON, J.R., BUERGLER, J.M., SPENCE, P.P., SHIMOTO, Y., ROBERTSON, T.L., KUNITADA, S., BOVILL, E.G., ARMSTRONG, P.W., HARRINGTON, R.A. & The XaNADU-PCI PILOT Investigators (2004). Initial experience with factor Xa inhibition in percutaneous coronary intervention: the XaNADU-PIC Pilot. J. Thromb. Haemost., 2, 234-241.
6. AMIRAL, J., LORMEAU, J.C., MARFAING-KOKA, A., VISSAC, A.M., BOYER-NEUMANN, C., TARDY, B., HERBERT, M. & MEYER, D. (1997). Absence of cross-reactivity of SR 90107A/ORG 31540 pentasaccharide with antibodies to heparin-PF4 complexes developed on heparin-induced thrombocytopenia. Blood Coagul. Fibrinolysis, 8, 114-117.
7. AOKI, Y., OHISHI, R., TAKEI, R., MATSUZAKI, O., MOHRI, M., SAITOH, K., GOMI, K., SUGIHARA, T., KIYOTO, T. & YAMAMOTO, S. (1994). Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III. Thromb. Haemost., 71, 452-455.
8. ARNLJOTS, B., EZBAN, M. & HEDNER, U. (1997). Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa. J. Vasc. Surg., 25, 341-346.
9. BAJAJ, M.S. & BAJAJ, S.P. (1997). Tissue factor pathway inhibitor: potential therapeutic applications. Thromb. Haemost., 78, 471-477.
10. BAJAJ, S.P., RAPAPORT, S.I. & MAKI, S.L. (1985). A monoclonal antibody to factor IX that inhibits the factor VII: Ca potentiation of factor X activation. J. Biol. Chem., 260, 11574-11580.
11. BANNER, D.W., D'ARCY, A., CHENE, C., WINKLER, F., GUHA, A., KONIGSBERG, W.H., NEMERSON, Y. & KIRCHHOFEV, D. (1996). The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature, 380, 41-46.
12. BAUER, K.A., ERIKSSON, M.D., LASSEN, M.R., TURPIE, A.G.G. & for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study (2001). Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after major elective knee surgery. N. Engl. J. Med., 345, 1305-1310.
13. BEIMOND, B.J., FRIEDERICH, P.W., LEVI, M., VLASUK, G.P., BULLER, H.R. & TEN CATE, J.W. (1996). Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation, 93, 153-160.
14. BENEDICT, C.R., RYAN, J., WOLITZKY, B., RAMOS, R., GERLACH, M., TIJBURG, P. & STERN, D. (1991). Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J. Clin. Invest., 88, 1760-1765.
15. BERNARD, G.R., VINCENT, J.L., LATERRE, F.F., LA ROSA, S.P., DHAINOUT, J.R., LOPEZ-RODRIGUEZ, A., STEINGRUB, J.S., GARBER, G.E., HELTERBRAND, J.D., ELY, E.W. & FISHER JR, C.W. (2001). Efficacy and safety of recombinant activated protein C for severe sepsis. N. Engl. J. Med., 344, 699-709.
16. BIJSTERVELD, N.R., MOONS, A.H., BOEKHOLDT, S.M., VAN AKEN, B.E., FENNEMA, H., PETERS, R.J., MEIJERS, J.C., BULLER, H.R. & LEVI, M. (2002). Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation, 106, 2550-2554.
17. BIJSTERVELD, N.R., VINK, R., VAN ARKEN, B.E., FENNEMA, H., PETERS, R.J., MEIJERS, J.C., BULLER, H.R. & LEVI, M. (2004). Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br. J. Haematol., 124, 653-658.
18. BITTL, J.A. (1995). Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators. Am. Heart J., 130, 658-665.
19. BITTL, J.A., CHAITMAN, B.R., FEIT, F., KIMBALL, W. & TOPOL, E.J. (2001). Bivalirudin verus heparin during coronary angioplasty for unstable or post-infarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am. Heart. J., 142, 952-959.
20. BITTL, J.A., STRONY, J., BRINKER, J., AHMED W.H. MECKEL, C.R., CHAITMAN, B.R., MARAGANORE, J., DEUTCH, E., ADELMAN, B. & for the Hirulog Angioplasty Study Investigators (1995). Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. N. Engl. J. Med., 333, 764-769.
21. BONEU, B., NECCIARI, J., CARIOU, R., SIE, P., GABAIG, A.M., KIEFFER, G., DICKINSON, J., LAMOND, G., MOELKER, H. & MANT, T. (1995). Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107A/ORG31540) with high affinity to antithrombin III in man. Thromb. Haemost., 74, 1468-1473.
22. BREDBERG, E., ANDERSSON, T.B., FRISON, L., THURESSON, A., JOHANSSON, S., ERIKSSON-LEPKOWSKA, M., LARSSON, M. & ERIKSSON, U.C. (2003). Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediatged drug-drug interactions. Clin. Pharmacokinet., 42, 765-777.
23. BROWNSTEIN, C., FALCONE, D.J., JACOVINA A.& HAJJAR, K.A. & HAJJAR, K.A. (2001). A mediator of cell surface-specific plasmin generation. Ann. NY Acad. Sci. U.S.A., 947, 143-155.
24. BRUFATTO, N. & NESHEIM, M.E. (2001). The use of prothrombin (S525C) labelled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation. J. Biol. Chem., 276, 17663-17671.
25. BULLER, H.R., DAVIDSON, B.L., DECOUSUS, H., CALLUS, A., GENT, M., PIOVELLA, F., PRINS, M.H., RASKOB, G., SEGERS, A.E., CARIOU, R., LEEUWENKAMP, O., LENSING, A.W. & MATISSE Investigators (2004). Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Intern. Med., 140, 867-873.
26. CLELAND, G.F., FREEMANTLE, N., KAYE, G., NASIR, M., VELAVAN, P., LALUKOTA, K., MUDAWI, T., SHELTON, R., CLARK, A.L. & COLETTA, A.P. (2004). Clinical trial update from the American Heart Association meeting: Omega-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHR, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORGIT and PAD and DEFINITE. Eur. J. Heart Failure, 6, 109-115.
27. COHEN, A.T., GALLUS, A.S., LASSEN, M.R., TOMKOWSKI, W., TURPIE, A.G.G., DAVIDSON, B.L., CARIOU, R.G., LENSING, A.W.A. & EGBERTS, J.F.M. (2003). Fondaparinux vs placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS). J. Thromb. Haemost. (Suppl. 1) (Abstr. #P2046).
28. COLWELL, C., BERKOWTIZ, S.D., COMP, P.C., LIEBERMAN, J.R., GINSBERG, J.S. & for the EXULT B Investigators (2003). Randomized double-blind comparison of ximelagatran, an oral direct thrombin inhibitor and warfarin to prevent venous thromboembolism (VTE) after total knee replacement. Blood, 102, 14 (Abstr. 39).
29. COLWELL, C.W., BERKOWITZ, S.D., DAVIDSON, B.L., LOTKE, P.A., GINSBERG, J.S., LIEBERMAN, J.R., NEUBAUER, J., MCELHATTAN, J.L., PETERS, G.R. & FRANCIS, C.W. (2003). Comparison of ximelagatran, an oral direct thrombin inhibitor with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J. Thromb. Haemost., 1, 2119-2130.
30. COUSSEMENT, P.K., BASSAND, J.P., CONVENS, C., VROLIX, M., BOLAND, J., GROLLIER, G., MICHELS, R., VAHANIAN, A., VANDERHEYDEN, M., RUPPRECHT, H.J. & VAN DE WERF, F. (2001). A synthetic factor Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. Eur. Heart J., 22, 1716-1724.
31. CREASEY, A.A., CHANG, A.C., FEIGEN, L., WUN, T.C., TAYLOR F.B, JR. & HINSHAW, L.B. (1993). Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Clin. Invest., 91, 2850-2856.
32. DAUD, A.N., AHSAN, A., IQBAL, O., WALENGA, J.M., SILVER, P.J., AHMAD, S. & FAREED, J. (2001). Synthetic heparin pentasacchardie depolymerization by heparinase: I: Molecular and biological implications. Clin. Appl. Thromb. Haemost., 7, 58-64.
33. DAVIE, E.W. (1995). Biochemical and molecular aspects of the coagulation cascade. Thromb. Haemost., 75, 1-6.
34. DEMPFLE, C.H. (2004). Minor transplacental passage of fondaparinux in vivo (Letter to the Editor). N. Engl. J. Med., 350, 1914-1915.
35. DUNWIDDIE, C., THORNBERRY, N.A., BULL, H.G., SARDANA, M., FRIEDMAN, P.A., JACOBS, J.W. & SIMPSON, E. (1989). Antistasin: a leech-derived inhibitor of factor Xa: kinetic analysis of enzyme inhibition and identification of the reactive site. J. Biol. Chem., 264, 16694-16699.
36. DYKE, C.K., BECKER, R.C., KLEIMAN, N.S., HOCHMAN, J.S., BOVILL, E.G., LINCOFF, A.M., GERSTENBLITH, G., DZAVIK, V., GARDNER, L.H., HASSELBLAD, V., ZILLMAN, L.A., SHIMOTO, Y., ROBERTSON, T.L., KUNITADA, S., ARMSTRONG, P.W. & HARRINGTON, R.A. (2002). First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation, 105, 2385-2391.
37. EIKELBOOM, J.W., ANAND, S.S., MALMBERG, K., WEITZ, J.I., GINSBERG, J.S. & YUSUF, S. (2000). Unfractionated heparin and low-molecular-weight heparin in acute coronary syndromes without ST-elevation: a meta-analysis. Lancet, 355, 1936-1942.
38. EISENBERG, P.R., SIEGEL, J.E., ABENDSCHEIN, D.R. & MILETICH, J.B. (1993). Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J. Clin. Invest., 191, 1877-1883.
39. ELALAMY, I., LECRUBIER, C., POTEVIN, F., ABDELOUAHED, M., BARA, L., MARIE, J.P. & SAMAMA, M. (1995). Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin dependent factor of twenty-five patients with heparin associated thrombocytopenia. Thromb. Haemost., 74, 1384-1385.
40. ELSAYED, Y.A., NAKAGAWA, K., KAMIKUBO, Y.I., ENJYOJI, K.I., KATO, H. & SUEISHI, K. (1996). Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model. Am. J. Clin. Pathol., 106, 574-583.
41. ERIKSSON, B.I., AGNELLI, G., COHEN, A.T., DAHL, O.E., LASSEN, M.R., MOURET, P., ROSENCHER, N., KALEBO, P., PANFILOV, S., ESKILSON, C., ANDERSSON, M., FREIJ, A. & EXPRESS Study Group (2003a). The direct thrombin inhibitor melagatran followed by ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J. Thromb. Haemost., 1, 2490-2496.
42. ERIKSSON, B.I., AGNELLI, G., COHEN, A.T., DAHL, O.E., MOURET, P., ROSENCHER, N., ESKILSON, C., NYLANDER, I., FRISON, L. & OGREN, M. (2003b). Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee joint replacement. Thromb. Haemost., 89, 288-296.
43. ERIKSSON, B.I., BAUER, K.A., LASSEN, M.R., TURPIE, A.G.G. & for the Steering Committee of the Pentasaccharide in Hip Fracture Surgery Study (2001). Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med., 345, 1340-1342.
44. ERIKSSON, B.I., BERGQVIST, D., KALEBO, P., DAHL, O.E., LINDBRATT, S., BYLOCK, A., FRISON, L., ERIKSSON, U.G., WELIN, L. & GUSTAFSSON, D. (2002). Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet, 360, 1441-1447.
45. ERIKSSON, B.I., DAHL, O.E., AHNFELT, L., KALEBO, P., STANGIER, J., NEHMIZ, G., HERMANSSON, K. & KOHLBRENNER, V. (2004). Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO 1. J. Thromb. Haemost., 2, 1573-1580.
46. ERIKSSON, B.I., LASSEN, M.R. & PENTasaccharide in Hip-FRActure Surgery Plus Investigators (2003c). Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicentre, randomized, placebo-controlled, double-blind study. Arch. Intern. Med., 163, 1733-1742.
47. ERIKSSON, H., WAHLANDER, K., GUSTAFSSON, D. & for the THRIVE I Investigators (2003). A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J. Thromb. Haemost., 1, 41-47.
48. ERIKSSON, U.G., BREDBERG, U., GISLEN, K., JOHANSSON, L.C., FRISON, L., AHNOFF, M. & GUSTAFSSON, D. (2003a). Pharmacokinetics and pharmacodynamic of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur. J. Clin. Pharmcol., 59, 35-43.
49. ERIKSSON, U.G., JOHANSSON, S., ATTMAN, P.O., MULEC, H., FRISON, L., FAGER, G. & SAMUELSSON, O. (2003b). Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin. Pharmcokinet., 42, 743-753.
50. ESMON, C.T. (1989). The roles of protein C and thrombomodulin in the regulation of blood coagulation. J. Biol. Chem., 264, 4743-4746.
51. ESMON, C.T., ESMON, N.L. & HARRIS, K.W. (1982). Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J. Biol. Chem., 257, 7944-7948.
52. ESMON, C.T. & OWEN, W.B. (1981). Identification of an endothelial cell cofactor for the thrombin-catalyzed activation of protein C. Proc. Natl. Acad. Sci. U.S.A., 78, 224-229.
53. ESMON, N.L., CARROLL, R.C. & ESMON, C.T. (1983). Thrombomodulin blocks the ability of thrombin to activate platelets. J. Biol. Chem., 258, 12268-12273.
54. ETTINGSHAUSEN, C.E., VELDMANN, A., BEEG, T., SCHNEIDER, W., JAGER, G. & KREUZ, W. (1999). Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin. Thomb. Hemost., 25, 537-541.
55. EXECUTIVE STEERING COMMITTEE ON BEHALF OF THE SPORTIF III INVESTIGATORS (2003). Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet, 362, 1691-1698.
56. FARNER, B., EICHER, P., KROLL, H. & GREINACHER, A. (2001). A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb. Haemost., 85, 950-957.
57. FERGUSSON, J.J. (2002). Meeting highlights - American Heart Association scientific sessions 2001. Circulation, 105, e37-e41.
58. FEUERSTEIN, G.Z., PATEL, A., TOOMEY, J.R., BUGELSKI, P., NICHOLS, A.J., CHURCH, W.R., VALOCIK, R., KOSTER, P., BAKER, A. & BLACKBURN, M.N. (1999a). Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arterioscler Thromb. Vasc. Biol., 19, 2554-2562.
59. FEURERSTEIN, G.Z., TOOMEY, J.R., VALOCIK, R., KOSTER, P., PATEL, A. & BLACKBURN, M.N. (1999b). An inhibitory antifactor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis. Thromb. Haemost., 92, 1443-1450.
60. FOX, I., DAWSON, A., LOYNDS, P., EISNER, J., FINDLEN, K., LEVIN, E., HANSON, D., MANT, T., WAGNER, J. & MARAGANORE, J. (1993). Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb. Haemost., 69, 157-163.
61. FRANCIS, C.S., BERKOWITZ, S.D., COMP, P.C., LIEBERMAN, J.R., GINSBERG, J.S., PAIMENT, G., PETERS, G.R., ROTH, A.W., MCELHATTAN, J. & COLWELL C.W. for the EXULT A Study Group (2003). Comparison of ximelagatran with warfarin for prevention of venous thromboembolism after total knee replacement. N. Engl. J. Med., 349, 1703-1712.
62. FRANCIS, C.W., GINSBERG, J.S., BERKOWITZ, S.D., BOUNAMOUX, H., DAVIDSON, B.L., ERIKSSON, H., FIESSINGER, J.N., HUISMANN, M., LUNDSTROM, T., NYSTROM, P. & for the THRIVE Treatment Study Investigators (2003). Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE Treatment Study. Blood, 102 (Suppl.), 6a (Abstract 7).
63. FRIEDMAN, D.G. (1987). The structure of thrombi. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 2nd edn. ed. Colman RW, Hirsh J, Marder V, Salzman EW., Philadelphia: JB Lippincott, (Chapter 71).
64. FUSTER, V. (1996). Elucidation of the role of plaque instability and rupture in acute coronary events. Curr. Opin. Cardiol., 11, 351-360.
65. GAYLE III, R.B., MALISZEWSKI, C.R., GIMPEL, S.C., SCHOENBORN, M.A., CASPARY, R.G., RICHARDS, C., BRASEL, K., PRICE, V., DROSOPOULOS, J.H., ISLAM, N., ALYONYCHEVEA, T.N., BOREKMAN, M.J. & MARCUS, A.J. (1998). Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39. J. Clin. Invest., 101, 1851-1859.
66. GIESEN, P.L., RAUCH, U., BOHRMANN, B., KLING, D., ROQUE, M., FALLON, J.T., BADIMON, J.J., HIMBER, J., RIEDERER, M.A. & NEMERSON, Y. (1999). Blood-borne tissue factor: another view of thrombosis. Proc. Natl. Acad. Sci. U.S.A., 96, 2311-2315.
67. GIRARD, T.J., MACPHAIL, L.A., LIKERT, K.M., NOVOTNY, W.F., MILETICH, J.P. & BROZE G.J, JR. (1990). Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein. Science, 248, 1421-1424.
68. GOLINO, P., RAGNI, M., CIRILLO, P., D'ANDREA, D., SCOGNAMIGLIO, A., RAVERA, A., BUONO, C., EZBAN, M., CORCIONE, N., VIGORITO, F., CONDORELLI, M. & CHIARELLO, M. (1998). Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent and arterial thrombosis. Circul. Res., 82, 39-46.
69. GOMI, K., ZUSHI, M., HONDA, G., KAWAHARA, S., MATSUZAKI, O., KARABAYASHI, T., YAMAMOTO, S., MARUYAMA, I. & SUZUKI, K. (1990). Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood, 75, 1396-1399.
70. GOULD, M.K., DEMBITZER, A.D., DOYLE, R.L., HASTIE, T.J. & GARBER, A.M. (1999a). Low-molecular-weight heparins compared with unfractionated heparin for treatment of deep venous thrombosis. A meta-analysis of randomized controlled trials. Ann. Intern. Med., 130, 800-809.
71. GOULD, M.K., DEMBITZER, A.D., SANDERS, G.D. & GARBER, A.M. (1999b). Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann. Intern. Med., 130, 789-799.
72. GREINACHER, A., JANSSENS, U., BERG, G., BOCK, M., KWASNY, H., KEMKES-MATTHES, B., EICHLER, P., VOLPEL, H., POTZSCH, B., LUZ, M. for the Heparin-Associated Thrombocytopenia Study (HAT) Investigators (1999a). Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation, 100, 587-593.
73. GREINACHER, A., VOLPEL, H., JANSSENS, U., HACH-WUNDERLE, V., KEMKES-MATTHES, B., EICHLER, P., MUELLER-VELTEN, H.G. & POTZSCH, B. for the HIT Investigators Group (1999b). Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation, 99, 73-80.
74. GUSTAFSSON, D. (2003). Oral direct thrombin inhibitors in clinical development. J. Int. Med., 254, 322-334.
75. GUSTAFSSON, D., NYSTROM, J., CARLSSON, S., BREDBERG, U., ERIKSSON, U., GYZANDER, E., ELG, M., ANTONSSON, T., HOFFMAN, K., UNGELL, A., SORESNSEN, H., NAGARD, S., ABRAHAMSSON, A. & BYLUND, R. (2001). The direct thrombin inhibitor melagatran and its oral prodrug H376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res., 101, 171-181.
76. HARKER, L.A., HANSON, S.R. & KELLY, A.B. (1997). Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb. Haemost., 78, 736-741.
77. HEIT, J.A., COLWELL, D.W., FRANCIS, C.W., GINSBERG, J.S., BERKOWITZ, S.D., WHILLPLE, J., PETERS, G. & for the AstraZeneca Arthroplasty Study Group (2001). Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. Arch. Intern. Med., 161, 2215-2221.
78. HERBERT, J.M., BERNAT, A., DOL, F., HERAULT, J.P., CREPON, B. & LORMEAU, J.C. (1996). DX-9065a, a novel synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J. Pharmacol. Exper. Ther., 276, 1030-1038.
79. HERBERT, J.M., HERAULT, J.P., BERNAT, A., VAN ARMSTERDAM, R.G., LORMEAU, J.C., PETITOU, M., VANBOECKEL, C., HOFFMAN, P. & MEULEMAN, D.G. (1998). Biochemical and pharmacological properties of SANORG 340006, a potent and long-acting synthetic pentasaccharide. Blood, 91, 4197-4205.
80. HIRSH, J. (1991a). Heparin. N. Engl. J. Med., 324, 1565-1574.
81. HIRSH, J. (1991b). Oral anticoagulant drugs. N. Engl. J. Med., 324, 1865-1875.
82. HOFFMAN, M., MONROE, D.M., OLIVER, J.A. & ROBERTS, H.R. (1995). Factors IXa and Xa play distinct roles in tissue-dependent initiation of coagulation. Blood, 86, 1794-1801.
83. HOGG, P.I. & JACKSON, C.M. (1989). Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc. Natl. Acad. Sci. U.S.A., 86, 3619-3623.
84. HUBER, D., CRAMER, E.M., KAUFMANN, J.E., MEDA, P., MASSE, J.M., KRUITHOF, E.K. & VISCHER, U.M. (2002). Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood, 99, 3637-3645.
85. JANG, Y., GUZMAN, L.A., LINCOFF, A.M., GOTTWAUNER-WOLF, M., FORUDI, F., HART, C.E., COURTMAN, D.W., EZBAN, M., ELLIS, S.G. & TOPOL, E.J. (1995). Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation, 92, 3041-3050.
86. JOHANSSON, L.C., FRISON, L., LOGREN, U., FAGER, G., GUSTAFSSON, D. & ERIKSSON, U.G. (2003). Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin. Pharmacokinet., 42, 381-392.
87. KEARON, C., COMP, P., DOUKETIS, J.D., ROYDS, R., YAMADA, K. & Gent, M. (2003). A dose-response study of a recombinant human soluble thrombomodulin (ART-123) for prevention of venous thromboembolism after unilateral total hip replacement. J. Thromb. Haemost. (Suppl. I) (Abstr. #OC330).
88. KONG, D.F., TOPOL, E.J., BITTL, J.A., WHITE, H.D., THEROUX, P., HASSELBLAD, V. & CALIFF, R.M. (1999). Clinical outcomes of bivalirudin for ischemic heart disease. Circulation, 100, 2049-2053.
89. LAGRANGE, F., VERGNES, C., BRUN, J.L., PAOLUCCI, F., NADAL, T., LENG, J.J., SAUX, M.C. & BANWARTH, B. (2002). Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb. Haemost., 87, 831-835.
90. LASSEN, M.R., BAUER, K.A., ERIKSSON, B.I., TURPIE, A.G.G. & for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee (2002). Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement in elective hip-replacement surgery: a randomised double-blind comparison. Lancet, 359, 1715-1720.
91. LASSEN, M.R., DAVIDSON, B.L., GALLUS, A., PINEO, G., ANSELL, J. & DEITCHMAN, D. (2003). A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, Razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery. Blood, 102, 15a (Abstract #41).
92. LASZIK, Z., MITRO, A., TAYLOR JR, F.B., FERRELL, G. & ESMON, C.T. (1997). Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation, 96, 3633-3640.
93. LEE, A., AGNELLI, G., BULLER, H., GINSBERG, J., HEIT, J., ROTE, W., VLASUK, G., COSTANTINI, L., JULIAN, J., COMP, P., VAN DER MEER, J., PIOVETTA, F., RASKOB, G. & GENT, M. (2001). Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation, 104, 74-78.
94. LENSING, A.W.A., PRANDONI, P., PRINS, M.H. & BULLER, H.R. (1999). Deep vein thrombosis. Lancet, 353, 479-485.
95. LEWIS, B.E., WALLIS, D.E., BERKOWITZ SD MATTHAI, W.H., FAREED, J., WALENGA, J.M., BARTHOLOMEW, J., SHAM, R., LERNER, R.G., ZEIGLER, Z.R., RUSTAGI, P.K., JANG, J.K., RIFKIN, S.D., MORAN, J., HURSTING, M.J., KELTON, J.G. & ARG-911 Study Investigators (2001). Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation, 103, 1838-1843.
96. LEWIS, B.E., WALLIS, D.E., LEYA, F., HURSTIN, M.J., KELTON, J.G. & for the Argatroban-915 Investigators (2003). Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch. Intern. Med., 163, 1849-1856.
97. LINCOFF, A.M. (2000). First clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: a randomized, double-blinded, dose-escalation trial assessing safety and efficacy of FFR-FVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial. JACC, 36, 312 (Abstract).
98. LINCOFF, A.M., BITTL, J.A., HARRINGTON, R.A., FEIT, F., KLEIMAN, N.S., JACKMAN, J.D., SAREMBOCK, I.J., COHEN, D.J., SPRIGGS, D., EBRAHIMI, R., KEREN, G., CARR, J., COHEN, E.A., BETRIU, A., DESMET, W., KEREIAKES, D.J., RUTSCH, W., WILCOX, R.G., DE FEYTER, P.J., VAHANIAN, A., TOPOL, E. & REPLACE-2 Investigators (2003). Bivalirudin and provisional GPIIb/IIIa blockade compared with heparin and planned GPIIb/ IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial. JAMA, 289, 853-863.
99. LINCOFF, A.M., KLEIMAN, N.S., KOTTKE-MARCHANT, K., MAIERSON, E.S., MARESH, K., WOLSKI, K.E. & TOPOL, E.J. (2002). Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am. Heart J., 143, 847-853.
100. LOLLAR, P., MACINTOSH, S.C. & OWEN, W.B. (1984). Reaction of antithrombin III with thrombin bound to the vascular endothelium: analysis in a recirculating perfused rabbit heart preparation. J. Biol. Chem., 259, 4335-4338.
101. MANNS, B.J., LEE, H., DOIG, C.J., JOHNSON, D. & DONALDSON, C. (2002). An economic evaluation of activated protein C treatment for severe sepsis. N. Engl. J. Med., 347, 993-1000.
102. MARUYAMA, I. (1999). Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb. Haemost., 82, 718-721.
103. MATISSE INVESTIGATORS (2003). Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med., 349, 1695-1702.
104. MURAYAMA, N., TANAKA, M., KUNITADA, S., YUMADA, H., INOUE, T., TERADA, Y., FUJITA, M. & IKEDA, Y. (1996). Tolerability, pharmacokinetics and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin. Pharmacol. Ther., 66, 258-264.
105. ORVIM, U., BARSTAD, R.M., VLASUK, G.P. & SAKARIASSEN, K.S. (1995). Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscl. Throm. Vasc. Biol., 15, 2188-2194.
106. PARKINSON, J.F., GRINNELL, B.W., MOORE, R.E., HOSKINS, J., VLAHOS, C.J. & BANG, N.U. (1990). Stable expression of a secretable deletion mutation of recombinant human thrombomodulin in mammalian cells. J. Biol. Chem., 265, 12602-12610.
107. PERSIST, INVESTIGATORS. (2004). A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J. Thromb. Haemost., 2, 47-53.
108. PETERSON, P. (2001). A long-term follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Blood, 98 (Suppl.), 2953 (Abstract).
109. PETERSEN, P., GRIND, M., ADLER, J. & SPORTIF II Investigators (2003). Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding tolerability, and safety study. J. Am. Coll. Cardiol., 41, 144:5-1451.
110. POTZCH, B., IVERSEN, S. & REISS, F.C. (1994). Recombinant hirudin as an anticoagulant in open-heart surgery: a case-report. Ann. Hematol., 68, A53.
111. QUINLAN, D.J., MCQUILLAN, A. & EIKELBOOM, J.W. (2004). Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann. Intern. Med., 140, 175-183.
112. RAGOSTA, M., GIMPLE, L.W., GERTZ, S.D., DUNWIDDIE, C.T., VLASUK, G.P., HABER, H.L., POWERS, E.R., ROBERTS, W.C. & SAREMBOCK, I.J. (1994). Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation, 89, 1262-1271.
113. REISS, F.C., LOWER, C. & SELLIG, C. (1995). Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J. Thorac. Cardiovasc. Surg., 11, 265-267.
114. REZAIE, A.R. (2001). Prothrombin protects factor Xa in the prothrombinase complex from inhibition by heparin-antithrombin complex. Blood, 97, 2308-2313.
115. SCHULMAN, S., WAHLANDER, K., LUNDSTROM, T., CLASON, S.B., ERIKSSON, H. & for the THRIVE III Investigators (2003). Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N. Engl. J. Med., 349, 1713-1721.
116. STANGIER, J., LIESENFELD, K.H., TROCONIZ, C.H., TILLMANN, I.F., SCHAEFER, H.G., HERMANSSON, K. & ERIKSSON, B.I. (2003a). The effect of BIBR953ZW, the active form of the oral direct thrombin inhibitor BIBR1048, on the prolongation of the aPTT and ECT in orthopedic patients: a population pharmacodynamic study. J. Thromb. Haemost., 1 (Suppl. 1), Abstract P1916).
117. STANGIER, J., NEHMIZ, G., LIESENFELD, K.N., HOLZSCHUH, I., HERMANSSON, K., SVAERD, R., DAHL, O.E., AHNFELT, L. & ERIKSSON, B.I. (2003b). Pharmacokinetics of BIBR953ZW, the active form of the oral direct thrombin inhibitor dabigatran etexilate, in patients undergoing hip replacement. J. Thromb. Haemost., 1 (Suppl. 1), abstract P1916.
118. STASSENS, P., BERGUM, P.W., GANSEMANS, Y., JESPERS, L., LAROCHE, Y., HUANG, S., MAKI, S., MESSENS, J., LAUWEREYS, M., CAPPELLO, M., HOTEZ, P.J., LASTERS, I. & VLASUK, G.D. (1996). Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc. Natl. Acad. Sci. U.S.A., 93, 2149-2154.
119. STRINGER, K.A. & LINDENFELD, J. (1992). Hirudins: antithrombin anticoagulants. Ann. Pharmacother., 26, 1535-1540.
120. TOLLEFSEN, D.M. (1995). Insight into the mechanism of action of heparin cofactor II. Thromb. Haemost., 74, 1209-1274.
121. TURPIE, A.G.G., BAUER, K., ERIKSSON, B.I., LASSEN, M.R. & for the Pentathlon 2000 Study Steering Committee (2002a). Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet, 359, 1721-1726.
122. TURPIE, A.G.G., BAUER, K.A., ERIKSSON, B.I., LASSEN, M.R. & for the Steering Committees of the Pentasaccharide Orthopedic (2002b). Prophylaxis studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med., 162, 1833-1840.
123. TUSZYUSKI, G., GASIC, T.B. & GASIC, G.J. (1987). Isolation and characterization of antistasin. J. Biol. Chem., 262, 9718-9723.
124. VLASUK, G.P. (1993). Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb. Haemost., 70, 212-216.
125. WALENGA, J., JESKE, W., BARA, L., SAMAMA, M.M. & FAREED, J. (1997). Biochemical and pharmacological rationale for the development of a synthetic heparin pentasaccharide. Thromb. Res., 86, 1-36.
126. WALENGA, J.M., JESKE, W.P., SAMAMA, M.M., FRAPAISE, F.X., BICK, R.L. & FAREED, J. (2002). Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert. Opin. Invest. Drugs, 11, 397-404.
127. WALENGA, J.M., KOZA, M.J., LEWIS, B.E. & PIFARRE, R. (1996). Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin. Appl. Thromb. Hemost., 2 (Suppl. 1), S21.
128. WALLENTIN, L., WILCOX, R.G., WEAVER, W.D., EMANUELSSON, H., GOODVIN, A., NYSTROM, P., BYLOCK, A. & for the ESTEEM Investigators (2003). Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM
129. WEITZ, J., LESLIE, B. & HUDOBA, M. (1998). Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation, 97, 544-552.
130. WEITZ, J.I. (1997). Low-molecular-weight heparins. N. Engl. J. Med., 337, 688-698.
131. WEITZ, J.I. & BULLER, H.R. (2002). Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation, 105, 1004-1011.
132. WEITZ, J.I., HUDOBA, M., MASSEL, D., MARAGANORE, J. & HIRSH, J. (1990). Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest., 86, 385-391.
133. WHITE, B., LIVINGSTONE, W., MURPHY, C., HODGSON, A., RAFFERTY, M. & SMITH, O.D. (2000). An open-label study of the adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood, 96, 3719-3724.
134. WIENE, W., NAR, H. & RIES, U.J. (2001a). Antithrombotic effects of the direct thrombin inhibitor BIBR953ZW and its orally active prodrug BIBR1048MS in a model of venous thrombosis in rabbits. Thromb. Haemost. (Suppl.) (Abstract OC583).
135. WIENE, W., NAR, H. & RIES, U.J. (2001b). Effects of the direct thrombin inhibitor BIBR953ZW and its orally active prodrug BIBR1048MS on experimentally-induced clot formation and template bleeding time in rats. Thromb. Haemost., 12 (Suppl.), (Abstract P761).